FyCkD_FuNnY Posted - 04/25/24

$KRRO @tctranfo hey buddy, chart not active, but stock is Live

insiderbuyingselling Posted - 04/24/24

$KRRO new insider buying: 17857 shares. http://insiderbuyingselling.com/?t=KRRO

insiderbuyingselling Posted - 04/24/24

$KRRO new insider buying: 17857 shares. http://insiderbuyingselling.com/?t=KRRO

insiderbuyingselling Posted - 04/24/24

$KRRO new insider buying: 17857 shares. http://insiderbuyingselling.com/?t=KRRO

FyCkD_FuNnY Posted - 04/24/24

$KRRO $70m Private Placement @ $56 Deep Track Capital leading Financing

insiderbuyingselling Posted - 04/23/24

$KRRO new insider buying: 17857 shares. http://insiderbuyingselling.com/?t=KRRO

johnnygogogo Posted - 04/22/24

$PRQR what would be a reasonable, ie. very conservative royalty that ProQR could command from every competitor that successfully gets an ADAR-based drug across the finish line? 7%? 10%? 12%? All it will take is one competitor to belly up to the bar and strike a deal for price discovery (and precedent). Start adding up the enterprise value of its competitors $WVE $KRRO Shape (private), ADARx (private), etc.

DonCorleone77 Posted - 04/18/24

$KRRO Korro Bio announces $70M private placement Korro Bio has entered into a subscription agreement with certain new and existing accredited investors to issue and sell an aggregate of 1,249,283 shares of its common stock in a private placement that is expected to result in gross proceeds of approximately $70.0 million, before deducting placement agent fees and estimated offering expenses. The PIPE is expected to close on April 22, 2024, subject to the satisfaction of customary closing conditions. The PIPE was led by funds affiliated with Deep Track Capital, with participation from Atlas Venture, Blue Owl Healthcare Opportunities, NEA, Rock Springs Capital, Tri Locum Partners, and other leading healthcare investors. Korro expects that the net proceeds from the PIPE along with its existing cash and equivalents of $166.4 million as of December 31, 2023, will provide runway to fund the completion of a Phase 1/2 trial of KRRO-110 in ZZ AATD patients, anticipated in 2026, progress additional liver and CNS pipeline programs into the clinic and its platform with a focus on delivery and machine learning, with the remainder used for working capital and general corporate purposes. Piper Sandler is acting as lead placement agent and RBC Capital Markets and BMO Capital Markets are acting as co-placement agents for the PIPE.

Stock_Titan Posted - 04/18/24

$KRRO Korro Announces $70 Million Private Placement https://www.stocktitan.net/news/KRRO/korro-announces-70-million-private-jfdq7ia6ymd9.html

eddoetwoshoes Posted - 04/03/24

$KRRO Help! What's happening???

Stock_Titan Posted - 1 month ago

$KRRO Korro to Participate in Upcoming Investor Conferences https://www.stocktitan.net/news/KRRO/korro-to-participate-in-upcoming-investor-h69167x4hop9.html

andreimatei Posted - 03/27/24

$KRRO strong movement recently. Good 2023 financial results. I need it to hit $559 to break even from the FREQ disaster. Lol basically impossible before the first readout in H2 2025, if ever, right? I’m biotech stupid but just got stuck on hopes and prayers to solve my personal need with FREQ. Regardless even this small recoup is welcomed.

Thestocktraderhubzee Posted - 03/27/24

$KRRO Piper Sandler Maintains Overweight on Korro Bio, Maintains $180 Price Target

Quantumup Posted - 03/27/24

RBC Capital⬆️PT $KRRO $90 was $70/Outperform~on⬆️conviction for A1AT — thinks KRRO can tackle a broader mkt (liver/lung) w/ preclin data, including non-human primates (NHP) that has shown pot for BiC; sees pot upside into $WVE clin data later this year. rhhby gsk $lly $inbx $sny

Estimize Posted - 03/27/24

$KRRO beats the Estimize EPS Consensus by $6.73 and reports inline with the Estimize Revenue Consensus. Reports FQ4 earnings of $-2.92 ... http://www.estimize.com/krro/fq4-2023?utm_content=beat_or_miss&utm_medium=tweet&utm_source=stocktwits

Stock_Titan Posted - 03/26/24

$KRRO Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress https://www.stocktitan.net/news/KRRO/korro-reports-full-year-2023-financial-results-and-highlights-recent-ti1bz8u8m2qr.html

valueforme Posted - 03/26/24

$KRRO vs $WWE - almost same market cap. Korro - AATD preclinical, IND in H2 2024, the rest is discovery. Wave - AATD in the clinic, GSK partnership, INHBE IND in 2024, clinical progress in WVE-N531 and WVE-003 as well. I do not undertand why Korro is worth around $700M

Longroader Posted - 03/13/24

$PRQR Good cash control...super low. £5.4m last 2 quarters. Data coming out mid24, wont be cheap for long. Catching up $WVE and $KRRO

kshonstocks Posted - 03/11/24

$KRRO has unusual volume for it today

valueforme Posted - 03/07/24

$PRQR @johnnygogogo "owns" is a very bold statement. PRQR has ADAR patents on that are used in $WVE and $KRRO AATD drug candidates. If WVE-006 is a real deal, then they will figure out the patent licensing agreemtent. I think by that time the discussion will be happening between Lilly and GSK and both PRQR and WVE will be acquired by respective parties. Long both.

Longroader Posted - 03/07/24

$PRQR $WVE $KRRO Wave $WVE reaching unicorn status....wow Come on small guy. $PRQR

RaffmanJoe Posted - 03/04/24

$KRRO 2.25M shares bought by insiders in November, started a small long position.

RaffmanJoe Posted - 03/04/24

$KRRO watching today

valueforme Posted - 02/29/24

$KRRO @Stocktwits It's publicly traded for months, please fix the price data stream for this ticker

dirkfrank Posted - 02/27/24

$KRRO what’s with the sp data?

Berakhot Posted - 02/27/24

$KRRO Webcast - Korro Bio at the TD Cowen 44th Annual Health Care Conference March 4, 2024 2:10 PM EST https://ir.korrobio.com/events/event-details/korro-bio-td-cowen-44th-annual-health-care-conference

halpy518 Posted - 02/27/24

$MREO Are you even trying to play the game? $KRRO running circles on you now.

Berakhot Posted - 02/27/24

$KRRO add to watch

Quantumup Posted - 02/27/24

BMO🏁 $KRRO ‘‘A Leader In RNA Editing W/ High Potential In AATD & Beyond,’’ at Outperform/$120: Unlike most AATD investigational Tx's, Korro's differentiated RNA editing approach🎯s both liver/lung manifestation/could pot'ly deliver a best-in-disease profile $mreo $wve $sny $vrtx

Stock_Titan Posted - 02/27/24

$KRRO Korro to Present at the TD Cowen 44th Annual Health Care Conference https://www.stocktitan.net/news/KRRO/korro-to-present-at-the-td-cowen-44th-annual-health-care-51rt3vfxwj4p.html